Clinical trial
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent…
NCT00386997 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT00386997 |
|---|---|
| Title | ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia |
| Official title | ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Fungal Infection |
| Intervention type | Drug |
| Interventions | liposomal amphotericin B (AmBisome®) |
| Enrollment | 20 |
| Start date | Nov 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Oct 12, 2006 |
| Last update posted | Aug 21, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: